A 6-basepair insert in the reverse transcriptase gene of human immunodeficiency virus type 1 confers resistance to multiple nucleoside inhibitors.
about
Comparison of sequencing by hybridization and cycle sequencing for genotyping of human immunodeficiency virus type 1 reverse transcriptaseA stable latent reservoir for HIV-1 in resting CD4(+) T lymphocytes in infected childrenA new point mutation (P157S) in the reverse transcriptase of human immunodeficiency virus type 1 confers low-level resistance to (-)-beta-2',3'-dideoxy-3'-thiacytidinePrevalence and characteristics of multinucleoside-resistant human immunodeficiency virus type 1 among European patients receiving combinations of nucleoside analoguesAmino acid deletion at codon 67 and Thr-to-Gly change at codon 69 of human immunodeficiency virus type 1 reverse transcriptase confer novel drug resistance profiles4'-Ethynyl nucleoside analogs: potent inhibitors of multidrug-resistant human immunodeficiency virus variants in vitroIn vitro HIV-1 evolution in response to triple reverse transcriptase inhibitors & in silico phenotypic analysisIncreased risk of Q151M and K65R mutations in patients failing stavudine-containing first-line antiretroviral therapy in CambodiaHIV-1 drug resistance and resistance testing.Selection of resistance-conferring mutations in HIV-1 by the nucleoside reverse transcriptase inhibitors (+/-)dOTC and (+/-)dOTFC.Increased multinucleoside drug resistance and decreased replicative capacity of a human immunodeficiency virus type 1 variant with an 8-amino-Acid insert in the reverse transcriptase.High-level resistance to 3'-azido-3'-deoxythimidine due to a deletion in the reverse transcriptase gene of human immunodeficiency virus type 1Relative replication fitness of a high-level 3'-azido-3'-deoxythymidine-resistant variant of human immunodeficiency virus type 1 possessing an amino acid deletion at codon 67 and a novel substitution (Thr-->Gly) at codon 69.Augmentation of human immunodeficiency virus type 1 subtype E (CRF01_AE) multiple-drug resistance by insertion of a foreign 11-amino-acid fragment into the reverse transcriptase.Functional correlates of insertion mutations in the protease gene of human immunodeficiency virus type 1 isolates from patients.An intact U5-leader stem is important for efficient replication of simian immunodeficiency virus.Structure and function of HIV-1 reverse transcriptase: molecular mechanisms of polymerization and inhibition.Genotypic testing for human immunodeficiency virus type 1 drug resistance.A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1Rapid and simple phenotypic assay for drug susceptibility of human immunodeficiency virus type 1 using CCR5-expressing HeLa/CD4(+) cell clone 1-10 (MAGIC-5)Genotypic and phenotypic resistance patterns of human immunodeficiency virus type 1 variants with insertions or deletions in the reverse transcriptase (RT): multicenter study of patients treated with RT inhibitorsHIV-1 antiretroviral resistance: scientific principles and clinical applicationsVirulence and reduced fitness of simian immunodeficiency virus with the M184V mutation in reverse transcriptase.Nucleoside analog resistance caused by insertions in the fingers of human immunodeficiency virus type 1 reverse transcriptase involves ATP-mediated excision.Insertions in the reverse transcriptase increase both drug resistance and viral fitness in a human immunodeficiency virus type 1 isolate harboring the multi-nucleoside reverse transcriptase inhibitor resistance 69 insertion complex mutation.Reversion of the M184V mutation in simian immunodeficiency virus reverse transcriptase is selected by tenofovir, even in the presence of lamivudine.Comparison of the Mechanisms of Drug Resistance among HIV, Hepatitis B, and Hepatitis C.HIV diversity and drug resistance from plasma and non-plasma analytes in a large treatment programme in western Kenya.Functional correlation between a novel amino acid insertion at codon 19 in the protease of human immunodeficiency virus type 1 and polymorphism in the p1/p6 Gag cleavage site in drug resistance and replication fitnessA novel genetic pathway of human immunodeficiency virus type 1 resistance to stavudine mediated by the K65R mutation.Predictors for the emergence of the 2 multi-nucleoside/nucleotide resistance mutations 69 insertion and Q151M and their impact on clinical outcome in the Swiss HIV cohort study.Update on didanosine.A Guide to HIV-1 Reverse Transcriptase and Protease Sequencing for Drug Resistance Studies.Protease inhibitor associated mutations compromise the efficacy of therapy in human immunodeficiency virus-1 (HIV-1) infected pediatric patients: a cross-sectional study.Transmitted HIV Drug Resistance Is High and Longstanding in Metropolitan Washington, DCInsertions in the human immunodeficiency virus type 1 protease and reverse transcriptase genes: clinical impact and molecular mechanisms.Persistence versus reversion of 3TC resistance in HIV-1 determine the rate of emergence of NVP resistance.NucAmino: a nucleotide to amino acid alignment optimized for virus gene sequencesHIV-1 amino acid changes among participants with virologic failure: associations with first-line efavirenz or atazanavir plus ritonavir and disease status.Amino acid mutation N348I in the connection subdomain of human immunodeficiency virus type 1 reverse transcriptase confers multiclass resistance to nucleoside and nonnucleoside reverse transcriptase inhibitors
P2860
Q24550959-1961D628-662E-4E29-AB56-A45F11A19F05Q24620746-19088DDB-309E-4B19-B376-9F8A5FCD158DQ28343476-2990EBDE-4011-4EFD-B639-B77B801F7E10Q28344476-A3676A7A-5C75-4DA3-B000-D391A9C6B9C5Q28361269-87C692C2-19C5-4C5F-98D8-B2C612D7AB23Q28362567-0BDEFE15-4F91-4E45-BFF0-1468916D43E3Q28486262-0F0B9F78-9202-484E-87B5-A9FEAF639482Q28535850-59C22FCE-961A-4872-A6CE-F22F7382D1A6Q30245693-83E17612-5BC6-4268-B890-03BA6F72D429Q32066792-1F5DF8BC-8DC2-41A1-B936-5FD23FC5D7D5Q33737755-B3CAE5CE-257F-44D3-AD47-AD2512F34899Q33796791-18D67A3D-7939-4A57-9EE7-E2309617BD8FQ33826453-43CF185E-0C71-458E-9E2B-048BE09303C9Q33841974-887CFE87-B0FB-4FBF-895C-3580E4941949Q33849423-323F107F-AA95-4EBA-9902-0A84A6C5F51CQ33850342-13E37192-6269-4DAC-B721-D5F1A409920EQ33896402-D68ED7AC-AFC9-4DFE-A6CD-B4E3C02645C2Q33906239-8851A692-B6FE-4C4E-B8AF-CB9877957F40Q33979107-E9CBD9DC-9536-4A01-944F-C940C8E3CC2CQ33981401-E1959526-7621-4D21-AF8D-ABFC0EF1BEE7Q33982354-72DF4C02-2514-4F22-90FB-2FEE49F9F37BQ34280466-84C92DD1-FEAB-40C4-8982-D894BE07DEF6Q34339657-E40128B3-6477-4C7A-917D-0F54C8B8AEF9Q34345605-3BB54EA0-09D2-4517-8B72-2973FF681827Q34348774-35B7C4DC-0637-4322-BE10-FA4D0671E76BQ34465037-BEB7713A-D76E-45A5-B4D1-B2321B771256Q34489239-8D4CFB98-E348-484E-A1CE-6ABE434C1B56Q34549498-CD905783-2A1C-4D4A-A3D8-0E2493F6E608Q34651403-BF784493-4248-4A8D-9DD5-2A476D9B4CD6Q34976902-4F36DD05-A380-4503-9E31-277025D15090Q35057734-4EA77E79-C5FB-4927-9EA4-F6373785A9ADQ35207285-C32BA1A1-39D6-418A-81A8-FA65F812A150Q35742512-1757F387-36E9-427E-B8BA-335B12618DD7Q35962627-861C5746-4B03-414E-B439-902CAEFE11D8Q36053733-D470508B-8B3E-42A8-A443-73A9495DDE91Q36175788-C559DA77-E5F4-4A03-A341-B427DD673771Q36246775-BF263B7E-061C-4925-A50E-EE3335AA58A4Q36294376-8AD32B57-E278-4C1A-9864-1B21420E30D5Q36412256-4264E0F7-AA64-41E9-869C-250DD48585E5Q36498272-6617C764-8F81-41EF-B0E4-4808F425176C
P2860
A 6-basepair insert in the reverse transcriptase gene of human immunodeficiency virus type 1 confers resistance to multiple nucleoside inhibitors.
description
1998 nî lūn-bûn
@nan
1998年の論文
@ja
1998年学术文章
@wuu
1998年学术文章
@zh-cn
1998年学术文章
@zh-hans
1998年学术文章
@zh-my
1998年学术文章
@zh-sg
1998年學術文章
@yue
1998年學術文章
@zh
1998年學術文章
@zh-hant
name
A 6-basepair insert in the rev ...... ultiple nucleoside inhibitors.
@en
A 6-basepair insert in the rev ...... ultiple nucleoside inhibitors.
@nl
type
label
A 6-basepair insert in the rev ...... ultiple nucleoside inhibitors.
@en
A 6-basepair insert in the rev ...... ultiple nucleoside inhibitors.
@nl
prefLabel
A 6-basepair insert in the rev ...... ultiple nucleoside inhibitors.
@en
A 6-basepair insert in the rev ...... ultiple nucleoside inhibitors.
@nl
P2093
P2860
P356
P1476
A 6-basepair insert in the rev ...... ultiple nucleoside inhibitors.
@en
P2093
Coolley KL
Katzenstein DA
Merigan TC
Winters MA
P2860
P304
P356
10.1172/JCI4948
P407
P577
1998-11-01T00:00:00Z